



ZFW/S

PTO/SB/21 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

| | |
|--|---------------------|
| Application Number | 10/785,230 |
| Filing Date | February 25, 2004 |
| First Named Inventor | Tadamitsu Kishimoto |
| Art Unit | 1642 |
| Examiner Name | Laura B. Goddard |
| Total Number of Pages in This Submission | 214 |
| Attorney Docket Number | 046124-5042-01 |

ENCLOSURES (Check all that apply)

| | | |
|--|---|---|
| <input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Postcard; Copies of 19 references |
| Remarks | | |

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | | | |
|--------------|----------------------------|----------|--------|
| Firm Name | Morgan Lewis & Bockius LLP | | |
| Signature | | | |
| Printed name | Robert Smyth, Ph.D. | | |
| Date | July 12, 2007 | Reg. No. | 50,801 |

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

| | | | |
|-----------------------|--|------|--|
| Signature | | | |
| Typed or printed name | | Date | |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number



Effective on 12/08/2004.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL

For FY 2006

Applicant claims small entity status. See 37 CFR 1.27

| | |
|-------------------------|--------------|
| TOTAL AMOUNT OF PAYMENT | (\\$) 180.00 |
|-------------------------|--------------|

Complete if Known

| | |
|----------------------|---------------------|
| Application Number | 10/785,230 |
| Filing Date | February 25, 2004 |
| First Named Inventor | Tadamitsu Kishimoto |
| Examiner Name | Laura B. Goddard |
| Art Unit | 1642 |
| Attorney Docket No. | 046124-5042-01 |

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order None Other (please identify): _____

Deposit Account Deposit Account Number: 50-0310 Deposit Account Name: Morgan, Lewis & Bockius

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee
 Charge any additional fee(s) or underpayments of fee(s) Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

| Application Type | FILING FEES | | SEARCH FEES | | EXAMINATION FEES | |
|------------------|-------------|--------------|-------------|--------------|------------------|--------------|
| | Fee (\$) | Small Entity | Fee (\$) | Small Entity | Fee (\$) | Small Entity |
| Utility | 300 | 150 | 500 | 250 | 200 | 100 |
| Design | 200 | 100 | 100 | 50 | 130 | 65 |
| Plant | 200 | 100 | 300 | 150 | 160 | 80 |
| Reissue | 300 | 150 | 500 | 250 | 600 | 300 |
| Provisional | 200 | 100 | 0 | 0 | 0 | 0 |

2. EXCESS CLAIM FEES**Fee Description**

| | Small Entity |
|--|--------------|
| Each claim over 20 (including Reissues) | 50 25 |
| Each independent claim over 3 (including Reissues) | 200 100 |
| Multiple dependent claims | 360 180 |

| Total Claims | Extra Claims | Fee (\$) | Fee Paid (\$) | Multiple Dependent Claims |
|--------------|--------------|----------|---------------|---------------------------|
| - 20 or HP = | x | = | | Fee (\$) |

HP = highest number of total claims paid for, if greater than 20.

| Indep. Claims | Extra Claims | Fee (\$) | Fee Paid (\$) | |
|---------------|--------------|----------|---------------|----------|
| - 3 or HP = | x | = | | Fee (\$) |

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

| Total Sheets | Extra Sheets | Number of each additional 50 or fraction thereof | Fee (\$) | Fee Paid (\$) |
|--------------|--------------|--|----------|---------------|
| - 100 = | / 50 = | (round up to a whole number) x | = | |

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Fee under 37 C.F.R. 1.17(p)

Fee Paid (\$)

180.00

SUBMITTED BY

| | | | |
|-------------------|---------------------|---|------------------------|
| Signature | <i>Robert Smyth</i> | Registration No. (Attorney/Agent) 50,801 | Telephone 202-739-3000 |
| Name (Print/Type) | Robert Smyth, Ph.D. | | Date July 12, 2007 |

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT
Attorney Docket 046124-5042-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Tadamitsu Kishimoto et al.**)
Application No. **10/785,230**) Group Art Unit: **1642**
Filed: **February 25, 2004**) Examiner: **Laura B. Goddard**
For: **Vascularization Inhibitors**) Confirmation No.: **1453**

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(c)

Pursuant to 37 C.F.R. 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the document listed on the attached PTO-1449. This Information Disclosure Statement is being filed to the best of the undersigned's knowledge before the mailing date of a Notice of Allowance for the above-referenced application. Under the provisions of 37 C.F.R. 1.97(c), the Commissioner is hereby authorized in the attached fee transmittal to charge the fee of \$180.00 as specified by 37 C.F.R. 1.17(p).

Each reference cited in this information disclosure statement was first cited in a notice of opposition in the corresponding European Patent application EP 99909307.3 dated May 2, 2007. A copy of a notice of opposition filed by (1) Eli Lily and Company and (2) Strawman Limited in the corresponding European Patent application has been submitted as part of this information disclosure statement.

Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute prior art. If the Examiner applies any one of the documents as prior art against any claim in the application, and Applicants determine that the cited document does not constitute prior art under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or

07/13/2007 DEMMANU1 00000142 500310 10785230
01 FC:1806 180.00 DA

credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a
Constructive Petition for Extension of Time in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **July 12, 2007**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Ave., N.W.
Washington, D.C. 20004
202-739-3000

Respectfully submitted
Morgan, Lewis & Bockius LLP



Robert Smyth
Registration No. 50,801

INFORMATION DISCLOSURE CITATION

Attorney Docket 046124-5042-01

Application No. 10/785,320

(Use several sheets if necessary)

Applicants: Tadamitsu Kishimoto *et al.*

Page 1 of 1

PTO Form 1449

Filing Date: February 25, 2004

Group Art Unit: 1642

U.S. PATENT DOCUMENTS

| Document No. | Date | Name | Class | Sub-Class | Filing Date |
|--------------|------------|---------------------------|-------|-----------|-------------|
| 1. 5,378,725 | 01/03/1995 | Bonjouklian <i>et al.</i> | 514 | 453 | 06/19/1993 |
| 2. 5,525,625 | 06/11/1996 | Bridges <i>et al.</i> | 514 | 456 | 01/24/1995 |

FOREIGN PATENT DOCUMENTS

| Document No. | Date | Country | Class | Sub-Class | Translation |
|----------------|------------|---------|-------|-----------|-------------|
| 3. EP 0897980 | 02/24/1999 | EP | C12N | 15/12 | N/A |
| 4. WO 96/24598 | 08/15/1996 | PCT | C07F | 9/38 | N/A |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

| | |
|-----|--|
| 5. | Communication of Notice of Opposition for EP 99909307.3 filed by Eli Lily and Company dated May 2, 2007. |
| 6. | Communication of Notice of Opposition for EP 99909307.3 filed by Strawman Limited dated May 2, 2007. |
| 7. | Bleul <i>et al.</i> (1997), The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes, Proc. Natl. Acad. Sci. USA 94: 1925-1930. |
| 8. | Donzella <i>et al.</i> (1998), AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor, Nature Medicine 4: 72-77. |
| 9. | Doranz <i>et al.</i> (1997), A Small-molecule Inhibitor Directed against a Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor, J. Exp. Med. 8: 1395-1400. |
| 10. | Eliceiri <i>et al.</i> (1998) Integrin $\alpha\beta 3$ Requirement for Sustained Mitogen-activated Protein Kinase Activity during Angiogenesis, J. Cell. Biol. 140: 1255-1263. |
| 11. | Felszeghy <i>et al.</i> (2004) Dexamethasone Downregulates Chemokine Receptor CXCR4 and Exerts Neuroprotection against Hypoxia/Ischemia-Induced Brain Injury in Neonatal Rats, Neuroimmunomodulation 11: 404-413. |
| 12. | Gupta <i>et al.</i> (1998), Chemokine Receptors in Human Endothelial Cells, J. Biol Chem. 273: 4282-4287. |
| 13. | Hanahan <i>et al.</i> (1998), Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis, Cell 86: 352-364. |
| 14. | Jackson <i>et al.</i> (1998) Pharmacological Effects of SB 220025, a Selective Inhibitor of P38 Mitogen-Activated Protein Kinase, in Angiogenesis and Chronic Inflammatory Disease Models, J. Pharmacol. Exp. Therapeutic. 284: 687-692. |
| 15. | Murakami <i>et al.</i> (1997) A Small Molecule CXCRA Inhibitor that Blocks T Cell Line-tropic HIV-1 Infection, J. Exp. Med. 186: 1389-1393. |
| 16. | Oikawa <i>et al.</i> (1996) Potent inhibition of angiogenesis by wortmannin, a fungal metabolite, European Journal of Pharmacology 318: 93-96. |
| 17. | Rafii <i>et al.</i> (1998) Regulation of Trafficking of Bone-Marrow Derived CD34+KDR+ Endothelial Progenitor Cells, Angiogenesis and Cancer, Proceedings AACR Special Conference in Cancer Research. |
| 18. | Schols <i>et al.</i> (1997), Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4, J. Exp. Med. 186: 1383-1388. |
| 19. | Stedmans Medical Dictionary, 26th Ed. (1995), 85, 1182, 1909. |
| 20. | Strieter <i>et al.</i> (1995) Role of C-X-C chemokines as regulators of angiogenesis in lung cancer, J. Leukocyte Biol. 57: 752-761. |
| 21. | Whalen (1990), Solid tumours and wounds: transformed cells misunderstood as injured tissue?, The Lancet 336: 1489-1492. |

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.